Aspire Growth Partners LLC Cytom X Therapeutics, Inc. Transaction History
Aspire Growth Partners LLC
- $113 Billion
- Q1 2025
A detailed history of Aspire Growth Partners LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Aspire Growth Partners LLC holds 92,254 shares of CTMX stock, worth $193,733. This represents 0.08% of its overall portfolio holdings.
Number of Shares
92,254
Previous 40,780
126.22%
Holding current value
$193,733
Previous $42 Million
110.96%
% of portfolio
0.08%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding CTMX
# of Institutions
67Shares Held
44.8MCall Options Held
8.9KPut Options Held
47.9K-
Tang Capital Management LLC San Diego, CA6.72MShares$14.1 Million0.28% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$11 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.12MShares$10.7 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.93MShares$8.25 Million0.9% of portfolio
-
Acadian Asset Management LLC Boston, MA3.14MShares$6.59 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $138M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...